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Abstract The widely accepted catalytic cycle of cytochromes
P450 (CYP) involves the electron transfer from NADPH
cytochrome P450 reductase (CPR), with a potential for second
electron donation from the microsomal cytochrome b5/NADH
cytochrome b5 reductase system. The latter system only
supported CYP reactions inefficiently. Using purified proteins
including Candida albicans CYP51 and yeast NADPH cyto-
chrome P450 reductase, cytochrome b5 and NADH cytochrome
b5 reductase, we show here that fungal CYP51 mediated sterol
14K-demethylation can be wholly and efficiently supported by the
cytochrome b5/NADH cytochrome b5 reductase electron trans-
port system. This alternative catalytic cycle, where both the first
and second electrons were donated via the NADH cytochrome b5
electron transport system, can account for the continued
ergosterol production seen in yeast strains containing a disrup-
tion of the gene encoding CPR.
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1. Introduction
Cytochromes P450 (CYPs) are haem-thiolate proteins in-
volved in the oxidative metabolism of endogenous and xeno-
biotic compounds [1,2]. The post-genomic era is revealing a
huge number of such proteins that can be involved in biosyn-
thetic reactions in steroid, prostaglandin, secondary metabo-
lism and others. Most attention to date has been placed on
mammalian enzymes involved in xenobiotic metabolism, par-
ticularly as they are central to the metabolic fate of pharma-
ceuticals, chemical carcinogens and environmental organic
pollutants [3].
Cytochromes P450 are not self-su⁄cient enzymes and, for
function, eukaryotic microsomal forms require NADPH cyto-
chrome P450 reductase (CPR) as an electron donor [4]. In
early investigations of the mammalian electron transport sys-
tem, and of the P450 catalytic cycle, key features were estab-
lished [5^9]. To perform catalysis, P450 must receive two elec-
trons from NADPH via CPR. Cytochrome b5 has been
implicated as a component in this electron transfer cycle for
some cytochromes P450, being capable/involved in the trans-
fer of the second electron to P450, but not the ¢rst (Fig. 1).
For some cytochromes P450 a higher activity results from
participation of cytochrome b5 [10,11], while for CYP17 cy-
tochrome b5 can also act to alter the reaction undertaken by
this cytochrome P450 form suggesting a modulatory e¡ect on
the CYP active site might also occur [12,13]. The cytochrome
b5/NADH cytochrome b5 reductase electron transport path-
way is also involved in other non-CYP reactions of sterol
biosynthesis and in fatty acid metabolism [14].
Within the yeast Saccharomyces cerevisiae genome, only
three CYP genes were revealed which require CPR for func-
tion: CYP51, sterol 14K-demethylase, undertaking C14-de-
methylation of lanosterol; CYP61, sterol 22-desaturase,
undertaking C22-desaturation of ergosta-5,7-dienol (both in-
volved in the ergosterol biosynthetic pathway); and CYP56,
dityrosine hydroxylase, involved in yeast sporulation [15]. Ad-
ditionally, a further enzyme of the sterol biosynthetic pathway
requires CPR, namely squalene epoxidase [16]. Yeast gene
disruption studies on CPR indicated surprisingly that the pro-
tein was dispensible [17,18] and that ergosterol was the pre-
dominant sterol with or without CPR being present in strains
[17,19]. With possession of the full genome it was evident that
no further CPR gene sequences are present to compensate and
confer functional redundancy. Here we address directly the
potential of the yeast cytochrome b5/NADPH cytochrome
b5 reductase system to drive CYP51 using heterologous ex-
pression, puri¢cation and reconstitution of enzyme activity.
Biodiversity of the CYP catalytic system was indicated as
the yeast cytochrome b5/cytochrome b5 reductase system and
supported the catalytic cycle entirely and as e⁄ciently as
CPR, unlike the observations made previously with mamma-
lian enzymes.
2. Materials and methods
2.1. Cloning and heterologous expression of yeast cytochrome b5 and
NADH cytochrome b5 reductase
The GeneStorm yORF expression vectors pYES2/gs containing the
S. cerevisiae cytochrome b5 and NADH cytochrome b5 reductase
genes were obtained from Invitrogen and used as a source of recombi-
nant protein. The gene insert in each GeneStorm yORF expression
vector was PCR ampli¢ed, the fragments correctly sized and the ori-
entation veri¢ed. Each expression plasmid was transformed into com-
petent Escherichia coli strain DH5K with transformants selected on
LB plates containing 50 Wg/ml ampicillin. Following bacterial trans-
formation and isolation of plasmid DNA, expression vectors were
transformed into a host yeast strain, BY4743 (MATa/K leu2v0/
leu2v0 ura3v0/ura3v0 his3v0/hisv0 LYS2/lys2 MET15/met15v0) using
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published procedures [20]. Yeast transformants were grown at 28‡C,
250 rpm with 250 ml culture in 500 ml £asks. The media used con-
sisted of Difco yeast nitrogen base without amino acids supplemented
with 100 mg/l histidine and 100 mg/l leucine and 2% (w/v) glucose as
initial carbon source. Heterologous expression was induced when the
glucose was exhausted at a cell density of approximately 108 cells/ml.
The culture was left a further 4 h before galactose was added to a ¢nal
concentration of 3% (w/v). After 20 h induction, cells were harvested
by centrifugation, resuspended in bu¡er containing 0.4 M sorbitol, 50
mM Tris-HCl pH 7.4 and broken using a Braun disintegrator (Braun
GmbH, Mesungen, Germany) with four bursts of 30 s together with
cooling from liquid carbon dioxide. Cell debris was removed by cen-
trifugation at 1500Ug for 10 min using a MSE bench centrifuge. The
resulting supernatant was centrifuged twice at 10 000Ug for 20 min to
remove mitochondria and ¢nally at 100 000Ug for 90 min to yield the
microsomal fraction. This was resuspended using a Potter-Elvehjeim
glass homogeniser at about 10 mg protein/ml in the same bu¡er de-
scribed above.
2.2. Puri¢cation of yeast cytochrome b5 and NADH cytochrome b5
reductase
The microsomal fractions prepared from cells heterologously ex-
pressing each protein were solubilised in 100 mM potassium phos-
phate bu¡er, pH 7.4 containing 2% (w/v) sodium cholate for 1 h at
4‡C. Solubilised proteins was recovered after a 1 h centrifugation step
at 100 000Ug and diluted with a 20% (v/v) glycerol/NaCl solution to
25 mM potassium phosphate, 500 mM NaCl, 0.8% (w/v) sodium
cholate. The supernatant was applied directly to a ProBond resin
column (Invitrogen) previously equilibrated with a 25 mM potassium
phosphate bu¡er, pH 7.4 containing 500 mM NaCl and 0.8% (w/v)
sodium cholate. ProBond resin column allows the puri¢cation of re-
combinant proteins expressed so as to contain a C-terminal polyhis-
tidine sequence. The protein was recovered from the crude solubilised
microsomal fractions by high a⁄nity binding to divalent nickel ions
on the resin. The column was washed with equilibration bu¡er and
slowly eluted with the same wash bu¡er, but containing 300 mM
imidazole. Fractions containing cytochrome b5 and NADH cyto-
chrome b5 reductase were concentrated and stored at 380‡C until use.
2.3. Characterisation of cytochrome b5 and NADH cytochrome b5
reductase expression
Analysis of cytochrome b5 and NADH cytochrome b5 reductase
protein levels was made by immunoblotting. Puri¢ed proteins were
separated by electrophoresis on 12% gels (w/v) according to the meth-
od of Laemmli [21] and transferred to nitrocellulose. Detection of
recombinant proteins was determined using the anti-V5-HRP (horse-
radish peroxidase conjugated) antibody, which allows detection of
recombinant proteins containing the C-terminal V5 epitope [22].
The anti-V5-HRP antibody recognises the sequence -Gly-Lys-Pro-
Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr-. Immunodetection of
cytochrome b5 and NADH cytochrome b5 reductase was performed
using chloronaphthol as described previously [23].
2.4. Expression and puri¢cation of recombinant Candida albicans sterol
14K-demethylase
Yeast transformants were cultivated in yeast minimal medium con-
taining 1.34% (w/v) Difco yeast nitrogen base without amino acids,
100 mg/l L-histidine and 2% (w/v) glucose as initial carbon source.
Heterologous protein expression was induced after exhaustion of glu-
cose in the medium by addition of galactose to a ¢nal concentration
of 3% (w/v). After 24 h induction cells were harvested by centrifuga-
tion and mechanically disrupted [24]. Microsomes were obtained fol-
lowing 100 000Ug ultracentrifugation and the expressed CYP51 was
solubilised with 2% (w/v) sodium cholate and puri¢ed on g-amino-n-
octyl Sepharose 4B and hydroxyapatite as previously described [25].
2.5. Expression and puri¢cation of recombinant S. cerevisiae
cytochrome P450 reductase
S. cerevisiae JL20 transformants carrying native yeast CPR expres-
sion vector was grown in yeast minimal medium containing Difco
yeast nitrogen base without amino acids (1.34%, w/v), 100 mg/l L-
histidine and glucose (2%, w/v) at 30‡C until glucose was completely
consumed and then heterologous expression was induced with galac-
tose (3%, w/v) for 20 h [19,26]. Cells were harvested by centrifugation
and subjected to mechanical breakage. The microsomal component,
containing full length CPR, was isolated by ultracentrifugation. Puri-
¢cation of yeast CPR was carried out according to published proce-
dures [27].
2.6. Reconstitution of CYP51 activity with CPR and/or cytochrome b5
and NADH cytochrome b5 reductase
Each reaction mixture contained puri¢ed CYP51 (0.1 nmol) and the
indicated reductase system at equimolar concentrations (P450 reduc-
tase or cytochrome b5/NADH cytochrome b5 reductase) in a total
volume of 50 Wl. For reconstitution studies, 23 nmol of substrate,
24-methylene-24,25-dihhydrolanosterol, was dispersed in 50 Wg dilaur-
oylphosphatidylcholine (DLPC), sonicated until a white suspension
had formed and dried down under nitrogen. The mixture was redis-
solved with the enzymatic components of the reactions and NADPH
was added at a ¢nal concentration of 1 mM to the mixture to start the
reaction. All reactions were incubated at 37‡C and were terminated by
the addition of 5 ml methanol. Sterol substrate and metabolite were
extracted and analysed by gas chromatography/mass spectroscopy
[28].
Fig. 1. The catalytic cycle of cytochrome P450. NADPH cytochrome P450 reductase (CPR) supplies two electrons to P450 for catalysis via
NADPH. Cytochrome b5/NADH cytochrome b5 reductase complex has been implicated as a component in this electron transfer cycle for some
cytochromes P450, being involved in the transfer of the second electron to P450, but not the ¢rst. The catalytic cycle is initiated by binding of
the substrate (AH) to the oxidised cytochrome (P4503).
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3. Results
3.1. Heterologous expression and puri¢cation of S. cerevisiae
cytochrome b5 and NADH cytochrome b5 reductase
In order to investigate the role of S. cerevisiae cytochrome
b5 and NADH cytochrome b5 reductase in supporting CYP51
activity, GAL1 mediated heterologous expression was under-
taken using the yeast vector pYES2/gs containing both open
reading frames (ORFs) (obtained from the Genestorm collec-
tion of Invitrogen). The microsomal fractions prepared from
yeast expressing these proteins were probed with the anti-V5
antibody. The mobilities of the expressed proteins were higher
than their predicted molecular masses (14 kDa for cytochrome
b5 and 34 kDa for NADH cytochrome b5 reductase) as ex-
pected due to the presence of the C-terminal V5 epitope and
poly-His-tag (18 kDa for cytochrome b5 and 38 kDa for
NADH cytochrome b5 reductase). Western blots also revealed
that both proteins were expressed exclusively in the microso-
mal fractions of the yeast as expected (data not shown). Pu-
ri¢cation of both recombinant cytochrome b5 and NADH
cytochrome b5 reductase to homogeneity was achieved follow-
ing immobilised metal a⁄nity chromatography using Pro-
Bond resin, which utilises the metal binding domain encoded
by the polyhistidine tag. Both recombinant cytochrome b5 and
NADH cytochrome b5 reductase were solubilised in 2% (w/v)
sodium cholate and a⁄nity puri¢ed with the aid of the C-
terminal His-tag using an Ni-nitrilotriacetic acid agarose col-
umn. Recombinant cytochrome b5 reductase showed the ab-
solute absorption spectra characteristic of £avoproteins. The
oxidised form showed prominent peaks at 460 and 390 nm,
typical of a £avoprotein (Fig. 2A), and the 460 nm peak
disappeared when reduced by 100 WM NADH. These results
are typical of native cytochrome b5 reductase proteins puri¢ed
from other organisms [29,30]. The recombinant cytochrome b5
showed an absorption maximum at 413 nm (Fig. 2B), and the
dithionite-reduced form exhibited prominent peaks at 424, 526
and 557 nm. These spectral characteristics are typical of the
Fig. 2. A: Absolute absorption spectrum of puri¢ed, recombinant
yeast NADH cytochrome b5 reductase. Puri¢ed NADH cytochrome
b5 reductase, 0.2 nmol, was dissolved in 100 mM potassium phos-
phate bu¡er, pH 7.2, and the absolute spectra were recorded (solid
line, oxidised form). B: Absolute absorption spectrum of puri¢ed,
recombinant yeast cytochrome b5. Puri¢ed cytochrome b5, 0.2 nmol,
was dissolved in 100 mM potassium phosphate bu¡er, pH 7.2, and
the absolute spectra were recorded (solid line, oxidised form).
Dashed line represents the spectrum obtained with yeast microsomes
expressing the null vector.
Fig. 3. Catalytic activities of puri¢ed C. albicans CYP51 driven by cytochrome b5/NADH cytochrome b5 reductase complex. A: Gas chromato-
gram of 24-methylene-24,25-dihydrolanosterol (S) with a retention time located at 44 min. B: The conversion of 24-methylene-24,25-dihydrola-
nosterol (S, retention time 44 min) to 4,4-dimethylergosta-8,14,24(25)-trienol (P, retention time 40.8 min) catalysed by C. albicans CYP51 recon-
stituted with cytochrome b5/NADH cytochrome b5 reductase complex as monitored by gas chromatography/mass spectroscopy outlined in
Section 2. C: 24-Methylene-24,25-dihydrolanosterol 14K-demethylation. Conversion of 24-methylene-24,25-dihydrolanosterol to 4,4-dimethyler-
gosta-8,14,24(25)-trienol in the presence of C. albicans CYP51, NADPH and molecular oxygen.
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native cytochrome b5 proteins puri¢ed from other sources
[31,32].
When the oxidised form of the recombinant cytochrome b5
was incubated with the recombinant cytochrome b5 reductase
protein and 100 WM NADH, it was rapidly reduced and
showed an absolute absorption spectrum similar to that of
the dithionite-reduced form with a spectral maximum at 424
nm. The recombinant NADH cytochrome b5 reductase was
functionally active. No reduction of cytochrome b5 was ob-
served in the presence of NADPH and cytochrome b5 reduc-
tase, demonstrating that cytochrome b5 reductase did not
transfer the reducing equivalents from NADPH to cyto-
chrome b5.
3.2. Catalytic activity studies on sterol 14K-demethylase with
cytochrome b5, NADH cytochrome b5 reductase and
NADPH cytochrome P450 reductase (CPR)
Previously, we have reported that disruption of S. cerevisiae
NADPH cytochrome P450 reductase (CPR) gene resulted in a
strain accumulating ergosterol [19]. This indicated that the
cytochrome P450 sterol biosynthetic enzymes, namely sterol
14K-demethylase (CYP51) and sterol v22-desaturase (CYP61),
could receive electrons to utilise in their catalytic reaction
mechanisms from other electron donor proteins other than
CPR. To investigate if cytochrome b5/NADH cytochrome b5
reductase might be responsible we reconstituted with puri¢ed
C. albicans CYP51 to determine activity. A reconstituted sys-
tem containing CYP51, cytochrome b5 and NADH cyto-
chrome b5 reductase could catalyse the 14K-demethylation
of 24-methylene-24,25-dihydrolanosterol to 4,4-dimethylcho-
lesta-8,14,24(28)-trienol (Fig. 3). CYP51, receiving reducing
equivalents via the cytochrome b5/NADH cytochrome b5 re-
ductase complex, could catalyse sterol 14-demethylation of 24-
methylene-24,25-dihydrolanosterol with similar activity to
CPR mediated CYP51 sterol demethylation. Turnover num-
bers were comparable to those for CPR driven sterol demeth-
ylation. For CYP51+CPR reactions a KM of 21 and VMAX of
0.24 þ 0.04 were observed compared to CYP51+CYT
b5+CYT b5 reductase reactions where a KM of 21 and
VMAX of 0.19 þ 0.03 were found. KM was expressed as WM
and VMAX as nmol product formed/min/nmol C. albicans
CYP51. These values were similar to other reports on recon-
stituting the activity of this CYP [25,26]. When using rat cy-
tochrome b5 in place of the yeast enzyme, activity was below
the level of detection using this assay. In experiments, values
between 0.2^0.3 nmol product/min/nmol CYP51 were ob-
tained where within experiment variation between CPR driven
and cytochrome b5/NADH cytochrome b5 reductase driven
values for enzyme turnover was observed to be approximately
20%.
4. Discussion
Since the discovery of the cytochromes P450 and the ¢rst
characterisation of the systems during the 1960s, a role for
CPR as the electron donor reductase was recognised and re-
constitution of activity was achieved [5,6]. Early studies indi-
cated simultaneous addition of NADH could stimulate
NADPH-dependent microsomal monooxygenase activity
[33]. This NADH e¡ect was proposed to indicate a possible
involvement of cytochrome b5 and the NADH electron trans-
fer pathway in providing the second electron needed for
monooxygenase activity [34]. Further support for this belief
was obtained from immunological studies utilising anti-cyto-
chrome b5 antibodies [35,36] and the NADH electron transfer
pathway has only been observed to support CYP activity on
its own at sub-optimal levels. This model has been accepted as
a central belief regarding the CYP catalytic cycle, although for
some mammalian CYP forms no stimulation of activity has
been observed and also for particular substrates of certain
isoforms. In some CYP reactions cytochrome b5 has been
reported as an obligatory component [37], including the im-
portant drug metabolising enzyme, human liver CYP3A4 [11].
The presence of cytochrome b5 can also alter the type of
chemical reaction undertaken by CYP17 from 17-hydroxyla-
tion to the lyase reaction [12,13].
Fig. 4. An alternative catalytic cycle for cytochrome P450 in yeast. The results of the present study reveal yeast CYP mediated activity sup-
ported wholly by the cytochrome b5/NADH cytochrome b5 electron transport system. A fundamental di¡erence from the original framework
elucidated for mammalian CYP catalytic cycle is established.
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Yeast sterol biosynthesis is the most complete sterol path-
way for which a gene complement is available. Besides being a
model system for sterol studies it is also important as the
target of the commercially important ergosterol biosynthesis
inhibitors, which include the azole antifungal CYP51 inhibi-
tors, and for metabolic engineering studies to produce vitamin
D and steroids. The disruption of the gene encoding yeast
CPR (NCPR1 in yeast nomenclature) was ¢rst undertaken
and reported by Sutter and Loper [17]. Strains were viable,
and could synthesise ergosterol as the predominant sterol [19].
Clearly an e⁄cient electron donor system existed to support
CYP51 (sterol 14-demethylase; Erg11p) and CYP61 (sterol
22-desaturase, Erg5p) catalytic activity, as well as squalene
epoxidase (Erg1p), in the absence of further CPRs within
the yeast genome. Further evidence that cytochrome b5 might
be important in this role came from observations that a dou-
ble disruption of cytochrome b5 and CPR was lethal to the
cell [18]. The cytochrome b5/NADH cytochrome b5 electron
transport system also participates in other sterol biosynthetic
reactions such as C5-desaturation and C4-demethylation
[38,39]
We have addressed these issues using puri¢ed components
of the yeast NADPH-CPR and NADH cytochrome b5 elec-
tron transfer systems to support C. albicans CYP51 mediated
activity. We used GAL10- and GAL1-based yeast expression
systems to produce CYP51 and CPR and cytochrome b5 and
NADH cytochrome b5 reductase, respectively. Expression of
CYP51 and CPR was as reported previously. The GAL1-
based GeneStorm system expressed cytochrome b5 and
NADH cytochrome b5 reductase to high levels of s 5 mg
recombinant protein/l culture respectively, re£ecting an e⁄-
cient system for producing such membrane-bound enzymes.
This included the C-terminal addition of a V5 epitope for
immunological recognition and the His-tag for e⁄cient puri-
¢cation. After puri¢cation addition of the proteins in recon-
stitutions for CYP51 activity was undertaken with compari-
son to CPR supported activity. Our ¢ndings of e⁄cient CYP
mediated activity supported by the cytochrome b5/NADH cy-
tochrome b5 electron transport system indicate biodiversity
from the original framework elucidated for mammalian
CYP catalytic cycle where the second electrons could be de-
rived from cytochrome b5. A summary of this alternative elec-
tron transfer cycle is outlined in Fig. 4.
Why such biodiversity exists deserves further consideration
with regard to whether the mammalian information is appli-
cable for all organisms. No data from plants at present have
indicated the cytochrome b5/NADH cytochrome b5 reductase
system can support CYP activity, although cytochrome b5
appears important in stimulating some CYP activities [40].
In Mycobacteria a soluble CYP51 exists, probably supported
by £avodoxin/£avodoxin reductase systems, but the relation-
ship of this novel pathway of cholesterol biosynthesis to eu-
karyotes is unclear, although intriguing [41]. Within the ergo-
sterol biosynthetic pathway the continued production of sterol
in CPR gene disrupted strains was observed previously
[17,19]. The results presented here explain this observation
and reveal interchangability in yeast electron transport donor
for CYP51 and by extension to CYP61 and squalene epoxi-
dase also. The slight reduction in sterol content for the CPR
gene disrupted yeast strains analysed before might be due to
increased burden on the cytochrome b5/NADH cytochrome b5
electron transport system. We discussed previously the likely
evolution of CYP61 from CYP51, and the ability of the for-
mer to metabolise xenobiotics [28,42], and despite the changes
in reaction mechanism involved (14-demethylation to 22-de-
saturation) retention of the catalytic requirements for CYP61
is likely to have been maintained from CYP51. It is most
likely this alternative catalytic cycle will hold for fungal sterol
biosynthesis generally. A similar catalytic cycle cannot be ex-
cluded elsewhere throughout the Kingdoms of Life.
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